Lantern Pharma Inc
$ 3.03
-0.98%
31 Dec - close price
- Market Cap 34,224,300 USD
- Current Price $ 3.03
- High / Low $ 3.15 / 2.96
- Stock P/E N/A
- Book Value 0.87
- EPS -1.75
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.56 %
- ROE -1.05 %
- 52 Week High 6.12
- 52 Week Low 2.55
About
Lantern Pharma Inc. (LTRN) is a forward-thinking clinical-stage biotechnology firm headquartered in Dallas, Texas, dedicated to revolutionizing cancer therapy through precision oncology. Utilizing its proprietary technology platform, the company integrates artificial intelligence with genomic data to enhance drug discovery and tailor oncology treatments to individual tumor genetic profiles, ultimately improving therapeutic outcomes. Lantern is committed to a data-driven methodology that addresses the complexities of cancer treatment, positioning itself as a key innovator in the rapidly evolving field of oncology and aiming to meet the diverse needs of patient populations effectively.
Analyst Target Price
$22.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-13 | 2025-05-07 | 2025-03-17 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-18 | 2023-11-08 | 2023-08-09 | 2023-05-09 | 2023-03-20 |
| Reported EPS | -0.39 | -0.4 | -0.42 | -0.54 | -0.42 | -0.46 | -0.51 | -0.39 | -0.29 | -0.44 | -0.36 | -0.31 |
| Estimated EPS | -0.44 | -0.53 | -0.43 | -0.51 | -0.56 | -0.55 | -0.43 | -0.4 | -0.45 | -0.43 | -0.48 | -0.47 |
| Surprise | 0.05 | 0.13 | 0.01 | -0.03 | 0.14 | 0.09 | -0.08 | 0.01 | 0.16 | -0.01 | 0.12 | 0.16 |
| Surprise Percentage | 11.3636% | 24.5283% | 2.3256% | -5.8824% | 25% | 16.3636% | -18.6047% | 2.5% | 35.5556% | -2.3256% | 25% | 34.0426% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LTRN
2025-12-20 09:10:06
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotech company using its proprietary RADR® A.I. platform for oncology drug discovery. The company's future hinges on the early 2026 readouts for its LP-184 and LP-300 drug candidates, which could either validate its AI platform and lead to a rerating of its shares or cause further investor disappointment. With no product revenue, Lantern Pharma relies on financing, partnerships, and grants, and its highly volatile stock reflects the high-risk, high-reward nature of early-stage biotech with significant cash burn and dilution concerns.
2025-12-05 08:08:53
Lantern Pharma announced positive Phase 1a results for LP-184, demonstrating durable disease control in heavily pre-treated advanced cancer patients, with a 54% disease control rate at therapeutic dose levels. The company is now advancing LP-184 into multiple biomarker-guided Phase 1b/2 clinical trials for cancers like TNBC, GBM, NSCLC, and urothelial carcinoma, supported by five FDA designations. These results, combined with their AI platform, highlight LP-184's potential as a precision oncology therapy.
2025-12-05 04:12:36
Lantern Pharma (NASDAQ: LTRN) announced encouraging results from its Phase 1a dose-escalation study of LP-184 in 63 heavily pre-treated patients with advanced solid tumors, meeting all primary safety and tolerability endpoints and establishing a recommended Phase 2 dose. The study showed durable disease control signals, particularly in tumors with DNA damage repair pathway deficiencies. The company plans to advance LP-184 into multiple biomarker-guided Phase 1b/2 trials, estimating a potential annual market opportunity exceeding $10 billion.
2025-12-05 04:12:36
Lantern Pharma (NASDAQ: LTRN) has released additional details from its completed Phase 1a dose-escalation study of LP-184. The study, involving 63 heavily pre-treated patients with advanced solid tumors, met all primary safety and tolerability endpoints and established a recommended Phase 2 dose. Encouraging signals of durable disease control were observed, particularly in tumors with DNA damage repair pathway deficiencies, leading to the advancement of biomarker-guided Phase 1b/2 trials across multiple cancer types.
2025-12-04 10:09:23
RedChip Companies will feature interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Lantern Pharma, Inc. (Nasdaq:LTRN) on its RedChip Small Stocks, Big Money™ show, airing Saturday, October 4, at 7 p.m. ET on Bloomberg TV. Enlivex's CEO will discuss positive Phase IIa results for Allocetra™ in knee osteoarthritis and its clinical roadmap, while Lantern Pharma's CEO will highlight their AI and machine learning platform, RADR®, for cancer drug discovery and development. Both companies are positioned for significant growth with upcoming clinical readouts and innovative approaches in their respective fields.
2025-12-04 04:12:36
Lantern Pharma (NASDAQ:LTRN) reported successful Phase 1a trial results for its lead AI-driven cancer drug candidate, LP-184. The trial demonstrated safety, tolerability, and durable disease control in heavily pre-treated patients with advanced solid tumors. The company is now planning multiple biomarker-guided Phase 1b/2 clinical trials for LP-184 across major cancer indications, projecting a multi-billion dollar market opportunity.
